WT1 Vaccine Doubles PFS in MPM Patients in Phase II Trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A phase II clinical study of the WT1 cancer vaccine, developed by SELLAS Life Sciences Group, showed increased median overall survival in patients with malignant pleural mesothelioma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login